Characterization of reduced astrocyte creatine kinase levels in Alzheimer's disease.

Autor: Zheng T; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden., Kotol D; Department of Proteomics and Nanobiotechnology, Royal Institute of Technology, Stockholm, Sweden., Sjöberg R; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden., Mitsios N; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden., Uhlén M; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Department of Proteomics and Nanobiotechnology, Royal Institute of Technology, Stockholm, Sweden., Zhong W; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Science for Life Laboratory, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden., Edfors F; Department of Proteomics and Nanobiotechnology, Royal Institute of Technology, Stockholm, Sweden., Mulder J; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Glia [Glia] 2024 Sep; Vol. 72 (9), pp. 1590-1603. Date of Electronic Publication: 2024 Jun 10.
DOI: 10.1002/glia.24569
Abstrakt: The creatine-phosphocreatine cycle serves as a crucial temporary energy buffering system in the brain, regulated by brain creatine kinase (CKB), in maintaining Adenosine triphosphate (ATP) levels. Alzheimer's disease (AD) has been linked to increased CKB oxidation and loss of its regulatory function, although specific pathological processes and affected cell types remain unclear. In our study, cerebral cortex samples from individuals with AD, dementia with Lewy bodies (DLB), and age-matched controls were analyzed using antibody-based methods to quantify CKB levels and assess alterations associated with disease processes. Two independently validated antibodies exclusively labeled astrocytes in the human cerebral cortex. Combining immunofluorescence (IF) and mass spectrometry (MS), we explored CKB availability in AD and DLB cases. IF and Western blot analysis demonstrated a loss of CKB immunoreactivity correlated with increased plaque load, severity of tau pathology, and Lewy body pathology. However, transcriptomics data and targeted MS demonstrated unaltered total CKB levels, suggesting posttranslational modifications (PTMs) affecting antibody binding. This aligns with altered efficiency at proteolytic cleavage sites indicated in the targeted MS experiment. These findings highlight that the proper function of astrocytes, understudied in the brain compared with neurons, is highly affected by PTMs. Reduction in ATP levels within astrocytes can disrupt ATP-dependent processes, such as the glutamate-glutamine cycle. As CKB and the creatine-phosphocreatine cycle are important in securing constant ATP availability, PTMs in CKB, and astrocyte dysfunction may disturb homeostasis, driving excitotoxicity in the AD brain. CKB and its activity could be promising biomarkers for monitoring early-stage energy deficits in AD.
(© 2024 The Author(s). GLIA published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: